Open AccessLDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project
Author(s) -
Leeuw Francisca A.,
Tijms Betty M.,
Doorduijn Astrid S.,
Hendriksen Heleen M. A.,
Rest Ondine,
van der Schueren Marian A. E.,
Visser Marjolein,
den Heuvel Ellen G. H. M.,
Wijk Nick,
Bierau Jörgen,
Berckel Bart N.,
Scheltens Philip,
Kester Maartje I.,
Flier Wiesje M.,
Teunissen Charlotte E.
Publication year - 2020
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1002/dad2.12120
Subject(s) - medicine , hazard ratio , dementia , homocysteine , endocrinology , cholesterol , biomarker , confidence interval , uridine , disease , gastroenterology , oncology , biology , biochemistry , rna , gene
We examined associations between nutritional biomarkers and clinical progression in individuals with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and Alzheimer's disease (AD)‐type dementia. METHODS We included 528 individuals (64 ± 8 years, 46% F, follow‐up 2.1 ± 0.87 years) with SCD (n = 204), MCI (n = 130), and AD (n = 194). Baseline levels of cholesterol, triglycerides, glucose, homocysteine, folate, vitamin A, B12, E and uridine were measured in blood and S‐adenosylmethionine and S‐adenosylhomocysteine in cerebrospinal fluid. We determined associations between nutritional biomarkers and clinical progression using Cox proportional hazard models. RESULTS Twenty‐two (11%) patients with SCD, 45 (35%) patients with MCI, and 100 (52%) patients with AD showed clinical progression. In SCD, higher levels of low‐density lipoprotein (LDL) cholesterol were associated with progression (hazard ratio [HR] [95% confidence interval (CI)] 1.88 [1.04 to 3.41]). In AD, lower uridine levels were associated with progression (0.79 [0.63 to 0.99]). DISCUSSION Our findings suggest that LDL cholesterol and uridine play a—stage‐dependent—role in the clinical progression of AD.